| Literature DB >> 15249045 |
Nancy L Wengenack1, Brian D Lane, Preston J Hill, James R Uhl, Gudrun S Lukat-Rodgers, Leslie Hall, Glenn D Roberts, Franklin R Cockerill, Patrick J Brennan, Kenton R Rodgers, John T Belisle, Frank Rusnak.
Abstract
Isoniazid, a first-line antibiotic used for the treatment of tuberculosis, is a prodrug that requires activation by the Mycobacterium tuberculosis enzyme KatG. The KatG(S315T) mutation causes isoniazid resistance while the KatG(R463L) variation is thought to be a polymorphism. Much of the work to date focused on isoniazid activation by KatG has utilized recombinant enzyme overexpressed in Escherichia coli. In this work, native KatG and KatG(S315T) were purified from M. tuberculosis, and KatG(R463L) was purified from Mycobacterium bovis. The native molecular weight, enzymatic activity, optical, resonance Raman, and EPR spectra, K(D) for isoniazid binding, and isoniazid oxidation rates were measured and compared for each native enzyme. Further, the properties of the native enzymes were compared and contrasted with those reported for recombinant KatG, KatG(S315T), and KatG(R463L) in order to assess the ability of the recombinant enzymes to act as good models for the native enzymes.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15249045 DOI： 10.1016/j.pep.2004.04.018
Source DB: PubMed Journal: Protein Expr Purif ISSN： 1046-5928 Impact factor: 1.650